Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Sees Significant Decrease in Short Interest
Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Get Free Report) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 2,570,000 shares, a decline of 6.2% from the October 31st total of 2,740,000 shares. Based on an average trading volume of 644,000 shares, the short-interest ratio is presently 4.0 days.
Institutional Investors Weigh In On Jazz Pharmaceuticals
Several large investors have recently added to or reduced their stakes in the business. US Bancorp DE grew its stake in Jazz Pharmaceuticals by 13.3% in the first quarter. US Bancorp DE now owns 2,736 shares of the specialty pharmaceutical company’s stock valued at $427,000 after acquiring an additional 322 shares during the period. Private Advisor Group LLC purchased a new position in Jazz Pharmaceuticals during the first quarter worth about $547,000. Aviva PLC grew its position in Jazz Pharmaceuticals by 87.1% during the first quarter. Aviva PLC now owns 40,005 shares of the specialty pharmaceutical company’s stock worth $6,228,000 after buying an additional 18,628 shares in the last quarter. Allianz Asset Management GmbH lifted its stake in shares of Jazz Pharmaceuticals by 118.2% in the 1st quarter. Allianz Asset Management GmbH now owns 12,130 shares of the specialty pharmaceutical company’s stock valued at $1,888,000 after acquiring an additional 6,571 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 5,602,650 shares of the specialty pharmaceutical company’s stock valued at $872,164,000 after purchasing an additional 57,949 shares during the last quarter. Institutional investors and hedge funds own 88.15% of the company’s stock.
Jazz Pharmaceuticals Price Performance
Jazz Pharmaceuticals stock opened at $119.11 on Monday. The company has a current ratio of 2.06, a quick ratio of 1.67 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.50 billion, a PE ratio of 135.35, a P/E/G ratio of 0.96 and a beta of 0.68. Jazz Pharmaceuticals has a 12 month low of $111.25 and a 12 month high of $160.96. The stock has a 50-day moving average price of $126.55 and a two-hundred day moving average price of $129.70.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported $4.22 earnings per share for the quarter, beating the consensus estimate of $4.21 by $0.01. The company had revenue of $972.14 million during the quarter, compared to analysts’ expectations of $969.47 million. Jazz Pharmaceuticals had a return on equity of 22.23% and a net margin of 2.11%. Analysts expect that Jazz Pharmaceuticals will post 15.41 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have commented on JAZZ. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a report on Tuesday, August 22nd. Bank of America upped their price objective on Jazz Pharmaceuticals from $204.00 to $217.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. UBS Group downgraded Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $170.00 to $135.00 in a research report on Monday, November 27th. HC Wainwright restated a “buy” rating and set a $204.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, August 11th. Finally, Raymond James started coverage on Jazz Pharmaceuticals in a research report on Thursday, September 28th. They set a “market perform” rating for the company. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $194.86.
Check Out Our Latest Analysis on Jazz Pharmaceuticals
Jazz Pharmaceuticals Company Profile (Get Free Report)
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Jazz Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Jazz Pharmaceuticals wasn’t on the list.
While Jazz Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of seven stocks and why their long-term outlooks are very promising.